Objective To explore the efficacy and safety of duloxetine plus quetiapine in treatment‐resist‐ant depression (TRD) .Methods Eighty TRD patients were randomly divided into two groups of 40 ones each ,research group took orally duloxetine plus quetiapine and control group did duloxetine for 8 weeks . Efficacies were assessed using the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The HAMD score lowered more significantly since the end of the 1st week in research group and since the 2nd in control compared with pretreatment (P<0 .01) ,so did that at each time‐point in research than in control group (P<0 .05 or 0 .01);at the end of the 8th week obvious effective and effective rate were respectively 79 .55% and 92 .3% in research and 50 .0% and 60 .5% in control group ,the former were significantly than the latter (χ2 =7 .35 ,7 .33;P<0 .01) .Adverse reactions of both groups were mild ,there were no significant group difference in the inci‐dence of adverse reactions .Conclusion Duloxetine plus quetiapine has a synergism ,takes effect more rapidly ,and has an evident effect ,higher safety and better compliance compared with single duloxetine in the treatment of treatment‐resistant depression .%目的：探讨度洛西汀联合喹硫平治疗难治性抑郁症的临床疗效和安全性。方法将80例难治性抑郁症患者随机分为两组，每组40例，研究组口服度洛西汀联合喹硫平治疗，对照组口服度洛西汀治疗，观察8周。采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果研究组治疗1周末起，对照组治疗2周末起，汉密顿抑郁量表评分较治疗前显著下降（P＜0．01），研究组治疗各时点评分显著低于对照组（P＜0．05或0．01）；治疗8周末研究组显效率79．5％、有效率92．3％，对照组分别为50．0％、60．5％，研究组显效率、有效率显著高于对照组（χ2＝7．35、7．33，P＜0．01）。两组不良反应均较轻微，发生率比较差异无显著性（ P＞0．05）。结论度洛西汀联合喹硫平治疗难治性抑郁症具有增效作用，起效快，疗效显著，安全性高，依从性好，优于单用度洛西汀治疗。
展开▼
